Epidermal growth factor receptor inhibitors in colorectal cancer treatment: What&rsquo;s new?

doi:10.3748/wjg.v13.i44.5877

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 44

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4254)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-4) series.

Item

Count

PDF

369

HTML

3487

Figures (1-1)

207

Tables (1-4)

191

Sum=4254

Nov 28, 2007 (publication date) through Dec 26, 2024

Times Cited of This Article

Times Cited (32)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. Nov 28, 2007; 13(44): 5877-5887
Published online Nov 28, 2007. doi: 10.3748/wjg.v13.i44.5877

Table 1 Cetuximab in Irinotecan refractory mCRC

	Pts (n)	RR (%)	PFS (mo)	OS (mo)
C225 + Innotecan[10]	121	17	-	-
C225[11]	57	9	-	6.4
C225 + Innotecan[13]	329	23	-	8.6

Pts: Patients; mCRC: Metastatic colorectal cancer; RR: Response rate; PFS: Progression free survival; OS: Overall survival; mo: Months; C225: Cetuximab.

Table 2 Cetuximab as frontline, Phase II studies

C225 plus:	Pts (n)	RR (%)	PFS (mo)	OS (mo)
FOLFIRI[25]	22	80	10.9	-
FOLFOX-4[22]	43	77	12.3	30
FOLFOX-6[26]	82	53	-	-

Pts: Patients; RR: Response rate; PFS: Progression free survival; OS: Overall survival; C225: Cetuximab.

Table 3 Cetuximab as frontline, Phase III studies

C225 plus:	Pts (n)	RR (%)	PFS (mo)	OS (mo)
FOLFOX Cetuximab vs FOLFOX[28]	337	46.6% vs 35.5%	-	-
FOLFIRI Cetuximab vs FOLFIRI[27]	1217	46.9% vs 38.7%	8.9 vs 8.0	-

Pts: Patients; RR: Response rate; PFS: Progression free survival; OS: Overall survival.

Table 4 Panitumumab, Phase II and III studies

	Pts (n)	RR (%)	PFS	Naive	Phase
Alone³⁰	148	10	-	No	II
Alone vs BSC³¹	463	10	8 wk	No	III
Alone³²	91	8	8 wk	No	II
IFL + Panitumumab vs FOLFIRI + Panitumumab³³	19 24	46 42	5.6 mo 10.9 mo	Yes	II

Pts: Patients; RR: Response rate; PFS: Progression free survival; OS: Overall survival; mo: months; BSC: Best supportive care.

Citation: Ponz-Sarvisé M, Rodríguez J, Viudez A, Chopitea A, Calvo A, García-Foncillas J, Gil-Bazo I. Epidermal growth factor receptor inhibitors in colorectal cancer treatment: What’s new? World J Gastroenterol 2007; 13(44): 5877-5887
URL: https://www.wjgnet.com/1007-9327/full/v13/i44/5877.htm
DOI: https://dx.doi.org/10.3748/wjg.v13.i44.5877